1

2
Tettelin Hervé, Masignani Vega: Group b streptococcus. Novartis Vaccines And Diagnostics, Tettelin Hervé, Masignani Vega, NOVARTIS VACCINES AND DIAGNOSTICS, June 29, 2006: WO/2006/069200 (5 worldwide citation)

Polypeptides and nucleic acids from Streptococcus agalactiae which can be used in the development of vaccines, for diagnostic purposes, and as targets for antibiotics.


3
Peretz David, Connolly Michael D, Zuckermann Ronald, Gao Man, Shimizu Robert M, Timoteo Gulliver: Prion-specific peptoid reagents. Novartis, Peretz David, Connolly Michael D, Zuckermann Ronald, Gao Man, Shimizu Robert M, Timoteo Gulliver, NOVARTIS VACCINES AND DIAGNOSTICS, March 15, 2007: WO/2007/030804 (2 worldwide citation)

The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at ...


4
Giuliano Bensi, Guido Grandi, Sergio Abrignani: Cytotoxic T-cell epitopes from. Novartis Vaccines and Diagnostics, Novartis Vaccines and Diagnostics, Silvia Brazzini, July 13, 2010: US07754228

Cytotoxic T-cell epitopes from C.pneumoniae proteins have been empirically determined. The epitopes from corresponding C.trachomatis proteins have also been identified, and some of these are identical to those from C.pneumoniae. The empirical method showed that algorithmic prediction was inadequate. ...


5
David Y Chien, Mark J Selby, Kevin Shoemaker, Robert L Warne: Protease regulator screening assay. Chiron Corporation, Novartis Vaccines And Diagnostics, December 28, 2006: US20060292659-A1

A polypeptide containing an anchor region, a protease recognition site, and a detectable signal region can be produced recombinantly and directly attached to a solid support. The polypeptide is useful for screening protease regulators, especially protease inhibitors.


6
Michael Houghton, Qui Lim Choo, George Kuo: Method of detecting antibodies to HCV. Chiron Corporation, Novartis Vaccines And Diagnostics, December 28, 2006: US20060292556-A1

A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B v ...


7
John M Polo, Silvia Perri, Kent Thudium: Chimeric alphavirus replicon particles. Chiron Corporation, Novartis Vaccines And Diagnostics, December 28, 2006: US20060292175-A1

Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or m ...


8
Laurence Elias, Gary W Witherell: Methods for treating renal cell carcinoma. Chiron Corporation, Novartis Vaccines And Diagnostics, January 18, 2007: US20070014765-A1

Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein sign ...


9
Amy J Weiner, Michael Houghton: Conserved motif of hepatitis C virus E2/NS1 region. Chiron Corporation, Novartis Vaccines and Diagnostics, Novartis Vaccines And Diagnostics, January 18, 2007: US20070014813-A1

The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is im ...


10
Pablo Garcia, Stephen F Hardy, Lewis T Williams, Jaime Escobedo: Endogenous retrovirus polypeptides linked to oncogenic transformation. Novartis Vaccines And Diagnostics, February 15, 2007: US20070037147-A1

HERV-K human endogenous retroviruses show up-regulated expression in tumors. In particular, splicing events in the env region generate a series of transcripts which utilise the +2 reading frame, relative to the env reading frame. The proteins show activity typical of transcriptional regulators, and ...